Kathleen Mulligan, PhD

CTSI Profile Photo

Kathleen Mulligan, PhD

User Profile Name
Professor, School of Medicine
CTSI Profile Title
User Profile Email

Biography

I study the nutritional and metabolic effects of chronic conditions including HIV infection and its therapies, obesity, fatty liver disease, and type 2 diabetes, with a focus on body composition, glucose and lipid metabolism, endocrine function, and bone metabolism; and a strong emphasis on treatments and mechanisms. My research has ranged from leading intense inpatient metabolic ward studies to chairing multicenter trials through consortia such as the adult and pediatric AIDS Clinical Trials Groups and Adolescent Trials Network.
CTSI Profile Bio

Displaying 51 - 75 of 100

  1. Taylor SA, Lee GA, Pao VY, Anthonypillai J, Aweeka FT, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. . 2010 Nov; 55(3):361-4.
  2. Rao MN, Mulligan K, Tai V, Wen MJ, Dyachenko A, Weinberg M, Li X, Lang T, Grunfeld C, Schwarz JM, Schambelan M. Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance. J Clin Endocrinol Metab. 2010 Sep; 95(9):4361-6.
  3. Jacobson DL, Lindsey JC, Gordon CM, Moye J, Hardin DS, Mulligan K, Aldrovandi GM, Pediatric AIDS Clinical Trials Group P1045 team . Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS. 2010 Mar 13; 24(5):687-96.
  4. Pao VY, Lee GA, Taylor S, Aweeka FT, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers. AIDS. 2010 Jan 16; 24(2):265-70.
  5. Raboud JM, Diong C, Carr A, Grinspoon S, Mulligan K, Sutinen J, Rozenbaum W, Cavalcanti RB, Wand H, Costagliola D, Walmsley S, Glitazone and Lipoatrophy Meta-Analysis Working Group . A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials. 2010 Jan-Feb; 11(1):39-50.
  6. Mulligan K, Harris DR, Monte D, Stoszek S, Emmanuel P, Hardin DS, Kapogiannis BG, Worrell C, Meyer WA, Sleasman J, Wilson CM, Aldrovandi GM, Adolescent Trials Network 021 Protocol Team . Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021. Clin Infect Dis. 2010 Jan 01; 50(1):106-14.
  7. Sakkas GK, Schambelan M, Mulligan K. Can the use of creatine supplementation attenuate muscle loss in cachexia and wasting? Curr Opin Clin Nutr Metab Care. 2009 Nov; 12(6):623-7.
  8. Campos GM, Rabl C, Peeva S, Ciovica R, Rao M, Schwarz JM, Havel P, Schambelan M, Mulligan K. Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg. 2010 Jan; 14(1):15-23.
  9. Lee GA, Schwarz JM, Patzek S, Kim S, Dyachenko A, Wen M, Mulligan K, Schambelan M, Grunfeld C. The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men. . 2009 Oct 01; 52(2):246-8.
  10. Aldrovandi GM, Lindsey JC, Jacobson DL, Zadzilka A, Sheeran E, Moye J, Borum P, Meyer WA, Hardin DS, Mulligan K, Pediatric AIDS Clinical Trials Group P1045 team . Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS. 2009 Mar 27; 23(6):661-72.
  11. Sakkas GK, Mulligan K, Dasilva M, Doyle JW, Khatami H, Schleich T, Kent-Braun JA, Schambelan M. Creatine fails to augment the benefits from resistance training in patients with HIV infection: a randomized, double-blind, placebo-controlled study. PLoS One. 2009; 4(2):e4605.
  12. Mulligan K, Khatami H, Schwarz JM, Sakkas GK, DePaoli AM, Tai VW, Wen MJ, Lee GA, Grunfeld C, Schambelan M. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab. 2009 Apr; 94(4):1137-44.
  13. Sattler FR, Rajicic N, Mulligan K, Yarasheski KE, Koletar SL, Zolopa A, Alston Smith B, Zackin R, Bistrian B, ACTG 392 Study Team . Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial. Am J Clin Nutr. 2008 Nov; 88(5):1313-21.
  14. Campos GM, Rabl C, Mulligan K, Posselt A, Rogers SJ, Westphalen AC, Lin F, Vittinghoff E. Factors associated with weight loss after gastric bypass. Arch Surg. 2008 Sep; 143(9):877-883; discussion 884.
  15. Ranade K, Geese WJ, Noor M, Flint O, Tebas P, Mulligan K, Powderly W, Grinspoon SK, Dube MP. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS. 2008 Aug 20; 22(13):1561-8.
  16. Sobieszczyk ME, Hoover DR, Anastos K, Mulligan K, Tan T, Shi Q, Gao W, Hyman C, Cohen MH, Cole SR, Plankey MW, Levine AM, Justman J, Women's Interagency HIV Study . Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. . 2008 Jul 01; 48(3):272-80.
  17. Grunfeld C, Kotler DP, Arnett DK, Falutz JM, Haffner SM, Hruz P, Masur H, Meigs JB, Mulligan K, Reiss P, Samaras K, Working Group 1 . Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation. 2008 Jul 08; 118(2):e20-8.
  18. Hulgan T, Tebas P, Canter JA, Mulligan K, Haas DW, Dubé M, Grinspoon S, Robbins GK, Motsinger AA, Kallianpur AR, AIDS Clinical Trials Group 384 and A5005s Study Teams . Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis. 2008 Mar 15; 197(6):858-66.
  19. Lee GA, Rao M, Mulligan K, Lo JC, Aweeka F, Schwarz JM, Schambelan M, Grunfeld C. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS. 2007 Oct 18; 21(16):2183-90.
  20. Dubé MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, Roubenoff R, Tebas P, Adult Clinical Trials Group 384 . Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. . 2007 Aug 15; 45(5):508-14.
  21. Li X, Youngren JF, Hyun B, Sakkas GK, Mulligan K, Majumdar S, Masharani UB, Schambelan M, Goldfine ID. Technical evaluation of in vivo abdominal fat and IMCL quantification using MRI and MRSI at 3 T. Magn Reson Imaging. 2008 Feb; 26(2):188-97.
  22. Dubé MP, Parker RA, Mulligan K, Tebas P, Robbins GK, Roubenoff R, Grinspoon SK. Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. Clin Infect Dis. 2007 Jul 01; 45(1):120-6.
  23. Mulligan K, Yang Y, Wininger DA, Koletar SL, Parker RA, Alston-Smith BL, Schouten JT, Fielding RA, Basar MT, Grinspoon S. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS. 2007 Jan 02; 21(1):47-57.
  24. Anastos K, Lu D, Shi O, Mulligan K, Tien PC, Freeman R, Cohen MH, Justman J, Hessol NA. The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antivir Ther. 2007; 12(7):1049-58.
  25. Brown CT, Yap T, Cromwell DA, Rixon L, Steed L, Mulligan K, Mundy A, Newman SP, van der Meulen J, Emberton M. Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ. 2007 Jan 06; 334(7583):25.